Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study

Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study

BackgroundA standard treatment recommendation for third-line and subsequent treatments for advanced HER2-positive breast cancer is still missing, especially for low HER2 expression. Nevertheless, there is evidence that these patients might benefits from antibody-drug conjugates (ADCs) treatment. The...

Full description

Bibliographic Details
Main Authors: Fei Qu, Rongrong Lu, Xinyu Wu, Qian Liu, Mengyao Zha, Huihui Li, Yuan Yuan, Zhengxiang Han, Dongyan Cai, Xiang Huang, Yongmei Yin, Wei Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
breast cancer
antibody-drug conjugates
Disitamab Vedotin
human epidermal growth factor receptor 2
efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1435485/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1435485/full

Similar Items